Trial
NCT04786574
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Intervention
Tolvaptan (OPC-41061)
Why stopped
Study stopped before enrolling any participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-24